

Long-term treatment with remibrutinib shows favorable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from a 52-week phase 2b extension study

A. Gimenez-Arnau, J. Tillinghast, V. Jain, S. Haemmerle, K. Lheritier, P. Walsh, S. Hugot, M. Wells, A. Zharkov, W. Carr

Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this [LINK](#) to access the abstract after 11th June 2023, once it is available at the congress website